Thomas Gronfeldt

@[email protected]
129 Followers
32 Following
73 Posts
#technology #innovation #futurism #food Still in betaverse.
More about what I dohttps://www.thomasgronfeldt.com
Corporate mehttp://www.linkedin.com/in/thomasgronfeldt
Thomas GronfeldtDec 21, 2022
Micah LeeDec 21, 2022
Oh hell yeah. @mozilla is launching a Mastodon instance in early 2023! I’m very excited for this. Mozilla is really good at what they do. Firefox has over 200M monthly active users, and with any luck they’ll build better support for the fediverse into Firefox itself. Mastodon will greatly benefit from easy to use professionally run instances that can handle massive scaling https://blog.mozilla.org/en/mozilla/mozilla-launch-fediverse-instance-social-media-alternative/
Mozilla to explore healthy social media alternative | The Mozilla Blog

Update: Starting May 4, 2023, we’re expanding Mozilla.social to a private beta. If you’re interested, join our waitlist. In early 2023, Mozilla will st

Thomas GronfeldtDec 21, 2022
Simon WillisonDec 21, 2022

Apparently there are people out there who think it's inappropriate to use Mastodon to talk about books you've written or promote projects you've worked on because it's marketing and self-promotion?

I am not one of those people. I implore you to write about the work you have done and the things you have made - I want to hear about that stuff!

Show threadThomas GronfeldtDec 16, 2022
This Friday's bit of #techoptimism, in the form of the #goodnews of the week: medical company Moderna has an mRNA cancer vaccine in testing that is showing a lot of promise. In a study on skin cancer, it reduced recurrence and death by a whopping 44 %, giving hope that in a very near future, we may have a vaccine for some kinds of the dreaded illness. https://www.freethink.com/health/mrna-cancer-vaccine?utm_source=tldrnewsletter
Moderna’s mRNA cancer vaccine reduces risk of recurrence or death by 44%

Moderna’s new mRNA cancer vaccine reduced melanoma patients’ risk of recurrence or death by 44% compared to a standard treatment alone.

Freethink Media
Thomas GronfeldtDec 13, 2022
I’ve been playing around with the iPhone’s photo options, and I’m quite impressed with what you can wrangle out of such a small device. The shot below uses Live Photo mode to emulate a long exposure shot, but taken free handed.
Thomas GronfeldtDec 12, 2022
Jay 🆘Dec 12, 2022
My suggestion if you want the Fediverse to work, follow and favorite and boost the absolute hell out of people. It’s not about dopamine or clout chasing, it’s about letting people know they’re not just typing into a void.
Thomas GronfeldtDec 12, 2022
We've long known that cognitive decline and hearing loss are connected. But one hypothesis is simply that they are caused by the same underlying reason; they're both symptoms of the same condition. But a new study shows that using hearing aids slows the cognitive decline, indicating that the hearing loss may be one of the causes of cognitive decline.
https://newatlas.com/health-wellbeing/hearing-aids-slow-cognitive-decline-dementia-metastudy/
Hearing aids slow cognitive decline, but reasons why still a mystery

A first-of-its-kind meta-analysis comprising more than 100,000 participants has found a significant association between the use of hearing aids and a reduced risk of dementia. The findings raise the curious suggestion that using hearing restoration devices could somehow slow the progression of…

New Atlas
Thomas GronfeldtDec 12, 2022
On the dangers (or strategic advantage for us in the case of the machine uprising) of historic data.
Thomas GronfeldtDec 12, 2022
Conrad Hackett Dec 12, 2022

"International Statistics of the Year" according to the Royal Statistical Society

Americans killed annually by
All Islamic jihadist terrorists 9
Armed toddlers 21
Lightning 31
Lawnmowers 69
Being hit by a bus 264
Falling out of bed 737
Being shot by another American 11,737

2017 winner: https://rss.org.uk/RSS/media/File-library/News/Press%20release/18-12-2017-THE-RSS-ANNOUNCES-ITS-STATISTIC-OF-THE-YEAR-FOR-2017.pdf

Show threadThomas GronfeldtDec 10, 2022
Whoops! One week in, and I'm already late. Oh well, here goes: This week's good news is that a new study has seen great results from using a patient's own immune cells, multiplied in a lab, to combat metastatic melanoma, one of the most aggressive forms of cancer. Any breakthrough in this area is great news! https://www.sciencedaily.com/releases/2022/12/221207183650.htm.
Patient's own immune cells effective as living medicine for melanoma

A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The TIL trial is the world's first comparative phase 3 trial looking into the effect of T cell therapy in melanoma, and solid tumors in general.

ScienceDaily
Thomas GronfeldtDec 9, 2022
Working in innovation, I often find that there's too much focus on "the idea", or rather, "THE idea". Getting ideas is easy, making them happen is hard. And one of the things I've seen many people struggle with is knowing *what* to work on, which ideas make more sense than others? So I've written up the prioritization paradigm my team uses to make sure we're focusing on what matters: https://thomasgronfeldt.com/2022/12/08/innovation-how-to-know-what-to-do/.
Innovation: How To Know What To Do

Thomas Grønfeldt Senger